SCRIBE THERAPEUTICS INC
SCTXNASDAQTrading Snapshot
- Day Range
- $22.93 – $23.39
- 52-Week Range
- $15.00 – $39.60
- Volume
- $2.81B
- Avg Volume
- $2.04B
- Shares Outstanding
- 16.2M
- Next Earnings
- Oct 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $51M
- Last Q Revenue
- $13M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own SCTX
- ✓High-growth profile — revenue up +29.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 57% gross margin and 8% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
SCRIBE THERAPEUTICS INC
SCTX
StockOtter · stockotter.spaceAbout SCRIBE THERAPEUTICS INC
Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Scribe Therapeutics Inc. (NASDAQ:SCTX) Stock Rated “Moderate Buy” by Wall Street Analysts
Scribe Therapeutics Inc. (NASDAQ: SCTX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five research firms that are covering the company, MarketBeat Ratings reports. One investment analy
Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to deliver ultra-long-acting cholesterol lowering witho
Scribe Therapeutics to Participate in Upcoming Investor Conferences
ALAMEDA, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed t
Here Are Monday’s Top Wall Street Analyst Research Calls: AGCO Corporation, Deere & Co., Edison International, Lumentum Holdings, PG&E, Sempra Energy, STAG Industrial, Ticketplus, and More
Rate hike fears rattled markets heading into the Labor Day weekend, and Wall Street analysts responded with a flurry of bold calls on utilities, farm equipment giants, and a ticketing upstart that could reshape your port
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
ALAMEDA, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to